{"id":"azilsartan-medoxomil-and-amlodipine","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL2028661","moleculeType":"Small molecule","molecularWeight":"568.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Azilsartan medoxomil is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors, reducing vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits L-type calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reduced blood pressure. The combination provides complementary antihypertensive effects through different mechanisms.","oneSentence":"Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels and reduce cardiac workload.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:17.641Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT06618079","phase":"PHASE1","title":"Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Huons Co., Ltd.","startDate":"2024-04-20","conditions":"Hypertension","enrollment":46},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT01762501","phase":"NA","title":"Azilsartan Circadian and Sleep Pressure","status":"COMPLETED","sponsor":"Sogo Rinsho Médéfi Co., Ltd.","startDate":"2012-12","conditions":"Hypertension","enrollment":957},{"nctId":"NCT02072330","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-03","conditions":"Grade I or II Essential Hypertension","enrollment":353},{"nctId":"NCT00591266","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-10","conditions":"Hypertension","enrollment":566}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Norvasc","TAK-491","Edarbi"],"phase":"phase_3","status":"active","brandName":"Azilsartan Medoxomil and amlodipine","genericName":"Azilsartan Medoxomil and amlodipine","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels and reduce cardiac workload. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}